Phase II trial of oxaliplatin with docetaxel followed by epidermal growth factor antibody (EGFR-AB) cetuximab in patients with recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)

Trial Profile

Phase II trial of oxaliplatin with docetaxel followed by epidermal growth factor antibody (EGFR-AB) cetuximab in patients with recurrent or metastatic squamous cell carcinoma of head and neck (SCCHN)

Discontinued
Phase of Trial: Phase II

Latest Information Update: 16 Jun 2017

At a glance

  • Drugs Cetuximab (Primary) ; Docetaxel (Primary) ; Oxaliplatin (Primary)
  • Indications Head and neck cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Aug 2012 Actual end date (Apr 2012) added as reported by ClinicalTrials.gov.
    • 02 Mar 2011 Planned end date changed from 1 Jan 2011 to 1 Dec 2011 as reported by ClinicalTrials.gov.
    • 23 Sep 2009 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top